Search
Returning search results with filters:
Remove filter for
Issue: COVID
Remove filter for
Last updated: 2022
Clear all
Type
Audience
Category
Issue
Last updated
- (-) 2022
- December 20221 results available
- November 20221 results available
- October 20222 results available
- September 20222 results available
- August 20222 results available
- June 20221 results available
- May 20222 results available
- April 20223 results available
- February 20225 results available
- January 20222 results available
Recall class
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archived checkbox.
Displaying 1 - 15 of 21 items.
On December 9, 2022, Health Canada authorized a new formulation of the bivalent vaccine, COMIRNATY Original & Omicron BA.4/BA.5, as a booster dose for active immunization against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory…
AlertHealth professional risk communication | 2022-12-09
Health Canada authorized SPIKEVAX Bivalent (Original / Omicron BA.4/5) (elasomeran/davesomeran) on November 3, 2022. In order to provide rapid access to the vaccine, Moderna will distribute product vials and cartons labelled in English only with the…
AlertHealth professional risk communication | 2022-11-18
EVUSHELD (tixagevimab and cilgavimab for injection) may not be effective against certain SARS-CoV-2 Omicron subvariants.
Audience
Healthcare professionals including physicians, pharmacists, nursing staff and public health officials.…
AlertHealth professional risk communication | 2022-10-26
On October 7, 2022, Health Canada authorized the bivalent vaccine, COMIRNATY Original & Omicron BA.4/BA.5, as a booster dose for active immunization against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2…
AlertHealth professional risk communication | 2022-10-07
Certain lots of hand sanitizers do not meet Health Canada requirements. Issues include:
containing (or possibly containing) ingredients that are not permitted by Health Canada;
containing undeclared impurities at elevated levels;
improper…
AlertPublic advisory | 2022-09-12
Health Canada authorized SPIKEVAX Bivalent (elasomeran/imelasomeran) on September 01, 2022. In order to provide rapid access to SPIKEVAX Bivalent, Moderna will distribute product vials and cartons labelled in English only with the brand name “SPIKEVAX 0…
AlertHealth professional risk communication | 2022-09-02
Ecotest Covid-19 Antigen Rapid Test Devices were sold without having the proper authorization from Health Canada.
Recall start date: August 11, 2022
RecallHealth product recall | 2022-08-24
Contains undeclared impurity, benzene, at elevated levels.
RecallHealth product recall | 2022-08-15
A new presentation of SPIKEVAX (elasomeran) with a concentration of 0.10 mg/mL in a 2.5 mL multidose vial was authorized on June 01, 2022. In order to provide rapid access to the new presentation of SPIKEVAX (0.10 mg/mL, 2.5 mL multidose vial), Moderna…
AlertHealth professional risk communication | 2022-06-06
Surestrips Covid-19 Antigen Tests are not authorized for sale in Canada as they were re-packaged into single tests and re-labelled without authorization by the manufacturers listed on the label (i.e. Artron Laboratories Inc.).
Recall start date…
RecallHealth product recall | 2022-05-30
Surestrips Rapid Response Covid-19 Antigen Rapid Test Device are not authorized for sale in Canada as they were re-packaged into single tests and re-labelled without authorization by the manufacturers listed on the label (i.e.…
RecallHealth product recall | 2022-05-30
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-04-21
EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with…
AlertHealth professional risk communication | 2022-04-14
Sotrovimab, 500 mg IV, is unlikely to maintain efficacy against the Omicron BA.2 subvariant. Sotrovimab demonstrates reduced in vitro neutralization against the Omicron BA.2 subvariant.
Audience
Healthcare professionals responsible…
AlertHealth professional risk communication | 2022-04-14
Following an increase in reports to poison control centres, Health Canada is advising Canadians about potential risks associated with the misuse or accidental ingestion or spillage of COVID-19 rapid antigen test kit solutions on the skin. Health Canada…
AlertPublic advisory | 2022-02-24